Using an animal model of D-galactose-induced osteoporosis (OP), the researchers examined the effects of resveratrol supplementation on body weight, alkaline phosphatase (ALP) levels and bone calcin (OC) levels and classified mice randomized into the following groups: Subgroup C (n=10): within 60 days participants will receive 1 ml of distilled water. In the D-galactose group (n=10), osteoporosis will be induced by intraperitoneal administration of 200 mg/kg/day of D-galactose for 60 consecutive days. Group R of 10 subjects will receive a dose of 25 mg/kg of oral resveratrol for 60 days.The DR group of the group of 10 subjects will receive D-galactose 200 mg/kg/day intraperitoneally in for osteoporosis and oral resveratrol at 25 mg/kg/day for 60 days. There was a distinct difference in body weight before and after OP infusion in each group in the study. The D-galactose group (D) showed significantly higher levels of ALP and OC compared with the control group. In contrast, the resveratrol group (R) showed significantly lower levels compared with the control group and the D group. Finally, the group treated with the combination of D-galactose and resveratrol (DR) showed significantly higher levels compared to the control group and the group treated with resveratrol alone (R). the. and more microfractures On the other hand, the resveratrol group (R) had thicker bone trabeculae, reduced intertrabecular space, and fewer microfractures. In addition, a protective effect against D-galactose-induced changes was observed in the resveratrol group, and these effects were dose-dependent The findings suggested resveratrol treatment in an animal model of osteoarthritis induced by D-galactose improved their weight, bone turnover markers (ALP and OC), and histological parameters were dependent on resveratrol levels.